Johns Hopkins Medicine researchers reported clinical validation supporting the first FDA-cleared rapid urine test to aid diagnosis of invasive aspergillosis. The work focuses on translating diagnostic performance into a tool designed for faster clinical decision-making, particularly in high-risk settings where early Aspergillus detection can change treatment pathways. With an FDA-cleared indication, the study sets a practical benchmark for how the test may be adopted in routine care and evaluated against existing diagnostic workflows. The clearance and validation together signal a near-term shift toward non-serum, point-of-care friendly detection in invasive fungal disease.